Please select the option that best describes you:
Do you ever extend adjuvant imatinib for patients with high-risk, localized GIST beyond 3 years?
If so, which patients would you extend treatment?
Answer from: Medical Oncologist at Academic Institution
The NCCN guidelines appropriately recommend "at least 3 yrs" of adjuvant Imatinib in intermediate to high risk, resected GIST. The decision to continue longer becomes a personalized one based on risk of recurrence, tolerance to Imatinib, coverage, etc. There are scenarios where both, the provider an...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
No.